vps-41 Antibody

What is VPS41 and what cellular functions does it perform?

VPS41 is a subunit of the HOPS (homotypic fusion and protein sorting) complex that plays essential roles in vesicle-mediated protein trafficking to lysosomal compartments, including endocytic membrane transport and autophagic pathways. In humans, the canonical protein has 854 amino acid residues with a molecular mass of 98.6 kDa. VPS41 acts as a core component of the HOPS endosomal tethering complex, mediating tethering and docking events during SNARE-mediated membrane fusion. It is critically involved in the Rab5-to-Rab7 endosome conversion process and regulates late endocytic, phagocytic, and autophagic traffic towards lysosomes .

Where is VPS41 predominantly expressed in human tissues?

VPS41 is predominantly expressed in neural tissues, particularly in the cerebral cortex and cerebellum. This expression pattern correlates with its association with neurological conditions such as Spinocerebellar ataxia (designated as SCAR29), highlighting its importance in maintaining neuronal homeostasis .

What are the known isoforms of VPS41 protein?

Up to three different isoforms of VPS41 have been reported in humans. These isoforms may exhibit tissue-specific expression patterns and potentially distinct functional properties. Research investigating these isoforms has demonstrated that they can have differential effects on cellular processes, as evidenced by experiments showing varying abilities to protect against α-synuclein toxicity .

What are the common synonyms and identifiers for VPS41?

When searching literature databases for VPS41, researchers should be aware of these synonyms: HVSP41, SCAR29, hVps41p, vacuolar protein sorting-associated protein 41 homolog, S53, and HVPS41. The gene ID (NCBI) is 27072, with GenBank accession number BC044851 and UniProt ID P49754 .

What criteria should be considered when selecting a VPS41 antibody for my research?

When selecting a VPS41 antibody, consider these key factors: (1) Species reactivity - confirm the antibody recognizes your species of interest, with documented cross-reactivity for human, mouse, and rat being most common; (2) Application compatibility - verify the antibody has been validated for your specific application (WB, IHC, ELISA, Co-IP); (3) Clonality - monoclonal antibodies offer higher specificity while polyclonal antibodies may provide stronger signals; (4) Epitope location - different antibodies target distinct regions of VPS41, which may influence detection of specific isoforms; and (5) Validation data - review published citations and validation data showing the antibody's performance in experimental conditions similar to yours .

How can I validate the specificity of a VPS41 antibody in my experimental system?

Rigorous antibody validation should include: (1) Positive and negative control samples - use tissues/cells known to express VPS41 (brain tissue, HepG2 cells, RAW 264.7 cells) versus those with low expression; (2) Knockdown/knockout validation - compare antibody reactivity in wild-type versus VPS41 knockdown/knockout samples; (3) Molecular weight verification - confirm detection at the expected 94-100 kDa range; (4) Multiple antibody comparison - use antibodies targeting different epitopes to confirm consistency; and (5) Peptide competition assay - pre-incubation with immunizing peptide should abolish specific signal .

What dilutions are recommended for different applications of VPS41 antibodies?

Optimal dilutions vary by application and specific antibody. Based on published protocols:

Always titrate antibodies in your specific experimental system to determine optimal working concentrations .

What are the most effective methods for detecting VPS41 by Western blotting?

For optimal Western blot detection of VPS41: (1) Prepare samples with adequate protease inhibitors to prevent degradation; (2) Use 7-10% polyacrylamide gels to adequately resolve the 98.6 kDa protein; (3) Transfer to PVDF membranes for 90-120 minutes at constant voltage; (4) Block with 5% non-fat milk or BSA; (5) Incubate with primary VPS41 antibody at 1:500-1:1000 dilution overnight at 4°C; (6) Wash thoroughly and incubate with HRP-conjugated secondary antibody; (7) Develop using enhanced chemiluminescence. This approach has successfully detected VPS41 in RAW 264.7 cells, HepG2 cells, and human brain tissue samples .

How can I optimize immunohistochemical detection of VPS41 in tissue sections?

For effective IHC detection of VPS41: (1) Fix tissues in 10% neutral buffered formalin; (2) Perform antigen retrieval using TE buffer pH 9.0 (alternatively citrate buffer pH 6.0); (3) Block endogenous peroxidase activity with 3% hydrogen peroxide; (4) Apply primary antibody at 1:50-1:500 dilution (start conservative and optimize); (5) Incubate overnight at 4°C; (6) Use appropriate detection system (HRP/DAB recommended); (7) Counterstain with hematoxylin. VPS41 typically shows cytoplasmic and perinuclear staining patterns, with particular enrichment in neuronal tissues and liver .

What approaches can be used to study VPS41 interactions with other proteins?

To investigate VPS41 protein interactions: (1) Co-immunoprecipitation (Co-IP) - use VPS41 antibodies to pull down protein complexes, followed by Western blotting for suspected interaction partners like Rab7, RILP, or ARL8B; (2) Proximity ligation assay (PLA) - visualize interactions in situ at subcellular resolution; (3) Yeast two-hybrid screening - identify novel interaction partners; (4) Fluorescence resonance energy transfer (FRET) - measure direct protein-protein interactions in living cells. When studying interactions within the HOPS complex, gentle lysis conditions using buffers containing 0.5-1% NP-40 or Triton X-100 are recommended to preserve protein complexes .

How can VPS41 antibodies be used to investigate autophagy and lysosomal function?

VPS41 antibodies can elucidate autophagy and lysosomal pathways through: (1) Co-localization studies - immunofluorescence microscopy to examine VPS41 distribution relative to autophagy markers (LC3, p62) and lysosomal proteins (LAMP1/2); (2) Autophagic flux assays - monitor VPS41 levels and localization during autophagy induction and inhibition; (3) Fractionation experiments - isolate autophagosomes and lysosomes to quantify VPS41 association with these compartments; (4) HOPS complex assembly analysis - investigate how perturbations in autophagy affect VPS41 incorporation into the HOPS complex. Since VPS41 is required for fusion of autophagosomes with lysosomes, antibody-based tracking can reveal rate-limiting steps in autophagic degradation pathways .

What is the relationship between VPS41 and neurodegenerative diseases, and how can antibodies help investigate this connection?

VPS41 has been implicated in neurodegenerative diseases, particularly through its association with Spinocerebellar ataxia (SCAR29) and potential neuroprotective effects against α-synuclein toxicity in Parkinson's disease models. Researchers can investigate these connections using VPS41 antibodies to: (1) Compare VPS41 expression and localization in patient-derived versus control tissues; (2) Assess VPS41 interaction with disease-associated proteins like α-synuclein; (3) Monitor VPS41 functional domains through directed antibodies against specific regions; (4) Evaluate the effect of disease-associated VPS41 variants (e.g., T146P and A187T SNPs) on protein function and localization. In cell culture models, VPS41 overexpression reduced α-synuclein inclusion formation by approximately 40%, suggesting a potential therapeutic relevance .

How can different functional domains of VPS41 be studied using domain-specific antibodies?

Domain-specific VPS41 antibodies can reveal structure-function relationships by: (1) Targeting specific functional domains (WD40 domain, RING-H2 finger domain, clathrin heavy chain repeat domain) to determine their localization and interaction partners; (2) Comparing wild-type versus truncated forms of VPS41 to identify domains critical for cellular protection; (3) Using epitope-specific antibodies to track conformational changes upon HOPS complex assembly; (4) Employing domain-specific antibodies in functional rescue experiments following endogenous VPS41 knockdown. Studies using truncated hVPS41 constructs have identified specific regions that retain neuroprotective function against α-synuclein toxicity, while others lose this ability, demonstrating the value of domain-specific investigations .

What are common issues when working with VPS41 antibodies and how can they be resolved?

Common challenges with VPS41 antibodies include: (1) Multiple bands in Western blots - may represent isoforms (~3 reported), degradation products, or non-specific binding. Resolution involves optimization of sample preparation with protease inhibitors, adjusting antibody concentration, or using alternative antibodies targeting different epitopes; (2) Weak signal - increase antibody concentration, extend incubation time, or enhance detection methods; (3) High background - increase blocking agent concentration, optimize washing steps, or pre-adsorb antibody; (4) Variability between experiments - standardize protocols, use consistent lot numbers, and include positive controls in each experiment .

How should VPS41 antibodies be stored and handled to maintain optimal activity?

For maximum antibody performance and longevity: (1) Store concentrated antibodies at -20°C in small aliquots to avoid freeze-thaw cycles; (2) For working dilutions, store at 4°C and use within 2 weeks; (3) Commercial VPS41 antibodies are typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, maintaining stability for one year when properly stored; (4) Some preparations may contain 0.1% BSA as a stabilizer; (5) Prior to use, centrifuge briefly to collect liquid at the bottom of the tube; (6) Allow antibodies to reach room temperature before opening to prevent condensation formation that can promote bacterial growth .

How can I quantitatively analyze VPS41 expression levels in different experimental conditions?

For accurate quantification of VPS41 expression: (1) Western blot densitometry - normalize VPS41 band intensity to loading controls (β-actin, GAPDH); (2) Quantitative immunofluorescence - measure fluorescence intensity of VPS41 staining relative to cell number or area; (3) qRT-PCR - quantify VPS41 mRNA levels using validated primer sets, normalizing to housekeeping genes; (4) ELISA-based quantification - develop sandwich ELISA using capture and detection antibodies with different epitope specificities. When comparing VPS41 levels across experimental conditions, include positive controls (e.g., human brain tissue for high expression) and negative controls (knockdown samples) to establish a dynamic range for quantification .